Keeping Up with the Rapidly Evolving Multiple Sclerosis Treatment Landscape – The Role for Health-System Pharmacists Web Activity

Release Date: May 1, 2022
Expiration Date: November 30, 2023
Estimated Time to Complete Activity: 1.0
Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:


	Mitzi Joi Williams, MD Founder Joi Life Wellness Group Click here for biography

	Aimee Banks, PharmD, BCPS, MSCS Clinical Pharmacist, Multiple Sclerosis Vanderbilt University Medical Center Click here for biography

Target Audience
This activity is designed to meet the educational needs of pharmacists with an interest managing patients with multiple sclerosis.

Statement of Need/Program Overview
Health care resource utilization associated with MS is significant and continues to rise. The continually evolving MS treatment landscape accentuates the need for increased disease and therapeutic knowledge amongst health-system pharmacy professionals to optimize clinical outcomes, reduce treatment variability, and increase patient engagement in their own care. Increased knowledge and competence will assist health-system pharmacy professionals in delivering quality care to MS patients and improving quality of life throughout the disease course.

Educational Objectives

Review the potential impact and value of real-world evidence to inform clinical decision making in MS
Assess where current and emerging therapies fit into the MS management algorithm
Evaluate the expanding role of telehealth and recommendations for managing MS management and treatment remotely
Illustrate treatment optimization approaches to balance costs with improved outcomes in MS management

Accreditation Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008162-9999-22-187-H01-P
Activity Type: Application

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Expert Faculty Presenters*	*Reported Financial Relationship*
Aimee Banks, PharmD, BCPS, MSCS	*Consulting fees (eg. Advisory boards)* – Bristol Myers Squibb; EMD Serono; TG Therapeutics
Mitzi Joi Williams, MD	*Consulting fees (eg. Advisory boards)* – Abbvie, Alexion, Biogen Idec, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Sanofi Genzyme *Contracted Research* – EMD Serono, Genentech, Novartis

The PIM planners and managers have nothing to disclose.
The Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

Complete the evaluation form
Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

FEE INFORMATION
There is no fee for this educational activity.